Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.

Schachter M.

Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. Review.

PMID:
15660968
2.
3.
5.

Clinical pharmacokinetics of statins.

García MJ, Reinoso RF, Sánchez Navarro A, Prous JR.

Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):457-81. Review.

PMID:
12949632
6.

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Lennernäs H, Fager G.

Clin Pharmacokinet. 1997 May;32(5):403-25. Review.

PMID:
9160173
7.

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.

Kajinami K, Takekoshi N, Saito Y.

Cardiovasc Drug Rev. 2003 Fall;21(3):199-215. Review.

PMID:
12931254
8.

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F.

Pharmacol Ther. 1999 Dec;84(3):413-28. Review. Erratum in: Pharmacol Ther 2000 May;86(2):199.

PMID:
10665838
9.

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

Igel M, Sudhop T, von Bergmann K.

Eur J Clin Pharmacol. 2001 Aug;57(5):357-64. Review.

PMID:
11599653
10.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
11.
12.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
13.

Pharmacological comparison of the statins.

Klotz U.

Arzneimittelforschung. 2003;53(9):605-11. Review.

PMID:
14558433
14.

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.

Pharmacotherapy. 2006 Apr;26(4):469-78.

PMID:
16553504
15.

New drugs for the treatment of hypercholesterolaemia.

Iglesias P, Díez JJ.

Expert Opin Investig Drugs. 2003 Nov;12(11):1777-89. Review.

PMID:
14585054
16.

A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.

Tárraga-López PJ, Celada-Rodríguez A, Cerdán-Oliver M, Solera-Albero J, Ocaña-López JM, López-Cara MA, De Miguel-Clave J.

Pharmacoeconomics. 2005;23(3):275-87. Erratum in: Pharmacoeconomics. 2006;24(1):106.

PMID:
15836008
17.

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacokinet. 2008;47(7):463-74. Review.

PMID:
18563955
18.

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.

Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H.

Int J Cardiol. 2005 Apr 20;100(2):309-16.

PMID:
15823640
19.

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Williams D, Feely J.

Clin Pharmacokinet. 2002;41(5):343-70. Review.

PMID:
12036392
20.

Supplemental Content

Support Center